摘要
目的通过临床、细胞形态学、细胞化学染色及分子生物学的检测对１例疑难病人进行诊断及鉴别诊断。方法运用细胞形态学、细胞化学染色及分子遗传学检测指标与临床相结合进行检查与分析。结果确诊１例罕见的Ｐｈ－／ｂｃｒ＋ＣＭＬ早期慢性期－红血病兼患淋巴瘤。结论该病例为十分罕见的多能干细胞克隆恶性增生疾病的多重癌罹患。其细胞形态学及分子生物学发现对诊断与鉴别诊断起了重要作用。
Objective The expression of bcl 2 in blasts from bone marrow of 46 patients with acute leukemia and its relation to apoptosis, cell proliferation, DNA ploidy and therapeutic effect were studied.Methods Using flow cytometric immunoassay.Results The results showed that the bone marrow blasts displayed various degree of bcl 2 expression(8.3%～47.7%) and apoptosis(3.0%～21.0%) in all the 46 cases. An inverse relationship between the extent of apoptosis and bcl 2 positivity was observed in the majority of cases.High bcl 2(≥20%) and low apoptosis(<15%)was noted in 11/13 cases(84.6%) while low bcl 2(<20%) and high apoptosis(≥15%) was demonstrated in 19/33 cases(57.6%). 14 cases(42.4%) had both low bcl 2 and low apoptosis and 2 exhibited high value for both parameters. In comparison with low bcl 2 cases,the high bcl 2 cases had low complete remission rate (6/13,46.1%,vs 29/33,87.9%),frequent DNA aneuploidy(11/13,84.6% vs 8/33,24.2%) and easy relapse (3/6,50% vs 2/29,6.9%). Conclusion Because of the heterogeneous expression,bcl 2 is not the sole factor regulating apoptosis, but it has prognostic significance and may play a role in the leukemogenesis.
出处
《白血病》
1999年第2期88-90,共3页
